FOLD
Amicus Therapeutics, Inc.
$9.5
Earnings Summary
Revenue | $141.52Mn |
Net Profits | $-6.73Mn |
Net Profit Margins | -4.75% |
Highlights
Amicus Therapeutics, Inc.’s revenue jumped 36.73% since last year same period to $141.52Mn in the Q3 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 11.72% jump in its revenue since last 3-months.
Amicus Therapeutics, Inc.’s net profit jumped 68.81% since last year same period to $-6.73Mn in the Q3 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 57.13% jump in its net profits since last 3-months.
Amicus Therapeutics, Inc.’s net profit margin jumped 77.19% since last year same period to -4.75% in the Q3 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 61.63% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Amicus Therapeutics, Inc. post its latest quarter earnings
EPS Estimate Current Year | -0.07 |
Highlights
Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.07.
Key Ratios
Key ratios of the Amicus Therapeutics, Inc. post its Q3 2024 earnings
Earning Per Share (EPS) | -0.02 |
Highlights
Amicus Therapeutics, Inc.’s earning per share (EPS) jumped 71.43% since last year same period to -0.02 in the Q3 2024. This indicates that the Amicus Therapeutics, Inc. has generated 71.43% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-11-06 | -0.01 | -0.02 | -100% |
2024-08-08 | -0.06 | -0.05 | 16.67% |
2024-05-09 | -0.07 | -0.16 | -128.57% |
₹0 US Stocks a/c Opening Fee